Clinical Trials Logo

Communicable Diseases clinical trials

View clinical trials related to Communicable Diseases.

Filter by:

NCT ID: NCT06387667 Not yet recruiting - Clinical trials for Immunocompromised ICU Patients With Respiratory Tract Infections

Characterizing Diversity and Antifungal Resistance in Immunocompromised ICU Patients With Respiratory Tract Infections

Start date: June 1, 2024
Phase: N/A
Study type: Interventional

Immunocompromised individuals face a heightened risk of life-threatening fungal infections, which arise from a multitude of environmental and commensal fungi. Surveillance data from ICUs worldwide identifies Candida spp. as the dominant foe, responsible for 80% of such infections, earning it the dubious distinction of being the third most prevalent pathogen. While C. albicans holds the dubious crown as the most common Candida offender, recent years have witnessed a concerning trend toward non-Albicans candida, raising concerns about potential antifungal resistance.

NCT ID: NCT06381882 Not yet recruiting - Pancreas Cancer Clinical Trials

The Role of the Human Microbiome in Patients After Pancreatic Resection.

MiPac
Start date: May 1, 2024
Phase:
Study type: Observational

The goal of this observational study is to classify patients that undergo pancreatic resection for presumed pancreatic or periampullary malignancy into high and low risk groups for postoperative complications based on longitudinal saliva, rectal/faecal, tumor, blood and/or bile microbiome profiles. To identify the dynamics of the microbiome, as well as the possibly related short-term and long-term complications, multiple samples at different timepoints are needed from the patients.

NCT ID: NCT06379035 Not yet recruiting - Colorectal Cancer Clinical Trials

Blastocystis and Cryptosporidium Infection in Colorectal Cancer Patients

Start date: November 1, 2024
Phase:
Study type: Observational

1. Detect the prevelance of Blastocystis spp. and Cryptosporidium spp. among patients with colorectal cancer attending South Egypt Cancer Institute-Assiut University. 2. Detect the effect of Blastocystis and Cryptosporidium infection on various cytokines level in CRC patients that may be involved in the tumor progression.

NCT ID: NCT06369220 Not yet recruiting - Clinical trials for Chlamydia Trachomatis Infection

A Study of the Cobas® Liat CT/NG/MG Test Versus Current Standard Practice for Managing Participants at Increased Risk of Sexually Transmitted Infections

Start date: June 15, 2024
Phase: N/A
Study type: Interventional

This study is designed to assess the comparative clinical utility of the point of care cobas® liat CT/NG/MG to current standard practices in the diagnosis and treatment of urogenital infections with Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Mycoplasma genitalium (MG).

NCT ID: NCT06368609 Not yet recruiting - Clinical trials for Strongyloides Stercoralis Infection

Preliminary Evaluation of Two Rapid Diagnostic Test Prototypes for Strongyloides Stercoralis Infection

PROTOSS
Start date: April 2024
Phase: N/A
Study type: Interventional

Single center, no profit experimental study on sera available in the Tropica Biobank.

NCT ID: NCT06368453 Not yet recruiting - Clinical trials for Human Immunodeficiency Virus I Infection

A Study to Evaluate the Performance, Usability, and Result Interpretation of INSTI® HIV Self-Test

Start date: May 1, 2024
Phase: N/A
Study type: Interventional

The objective of this study is to evaluate the performance, usability, and result interpretation of the INSTI® HIV Self-Test (referred to INSTI® HIV ST) in the intended use population across the United States (US). The INSTI® HIV Self-Test is a single use in vitro test that is used as a self-test for the detection of antibodies to HIV-1 and HIV-2 in human fingerstick blood. This study is designed to evaluate INSTI® HIV ST performance in the hands of non-professionals and untrained lay users who are inexperienced in HIV blood-based self-testing. The study aims to: To evaluate the clinical performance (i.e., diagnostic sensitivity and specificity) of the INSTI® HIV Self-Test in a lay user population. To assess the user's comprehension of the INSTI® HIV ST results (e.g., interpreting positive, negative, and invalid results). To evaluate the usability of the INSTI® HIV ST and understand users' experience in performing the test.

NCT ID: NCT06367504 Not yet recruiting - Clinical trials for Clostridium Difficile Infection

A Study to Assess the Effect of Doctor's Biome Medical Food in Individuals With Clostridium Difficile Infection

Start date: July 15, 2024
Phase: N/A
Study type: Interventional

A randomized, double-blind, placebo-controlled, pilot clinical study to assess the effect of Doctor's Biome Medical Food (DBMF) in individuals with Clostridium difficile infection (CDI)

NCT ID: NCT06363877 Not yet recruiting - Clinical trials for Surgical Site Infection

Diluted Aqueous Povidone-Iodine Compared to Saline to Decrease Surgical Site Infections

Start date: August 2024
Phase: Phase 3
Study type: Interventional

This is a multicenter randomized controlled trial of 1100 patients to evaluate the superiority of combined intraoperative wound irrigation with intraoperative peritoneal lavage with dilute aqueous povidone-iodine compared to normal saline in male and female patients between the ages of 18 and 80 years old undergoing emergency laparotomies with Centers for Disease Control (CDC) class 2 and 3 wounds.

NCT ID: NCT06362720 Not yet recruiting - Clinical trials for CMV Infection or Reactivation After Allogenic HSCT

The Comparison the CMV Infection and Reactivation After Allogeneic Hematopoietic Stem Cell Transplantation Between Standard Regimen, Methotrexate Plus Cyclosporin A, and Post-transplant Cyclophosphamide-based Regimen

CMV
Start date: May 1, 2024
Phase:
Study type: Observational

The goal of this observational study is to compare the CMV infection and reactivation after allogeneic hematopoietic stem cell transplantation Between Standard Regimen, Methotrexate plus Cyclosporin A, and Post-transplant Cyclophosphamide-based Regimen. The main questions it aims to answer are: - How do CMV infection and reactivation differ between Allo-SCT patients who received a standard regimen versus those who received a Post-transplant Cyclophosphamide-based regimen? - progression-free survival, Median overall survival, cumulative incidence of relapse, non-relapsed mortality (NRM) and GvHD at 2 years after Allo-SCT - The impact of CMV infection and CMV reactivation on progression-free survival, overall survival, and NRM - Averse events of GVHD prophylaxis medication Participants will be collected the data of treatment and treatment response during transplant until 2 years after transplant from hospital medical record.

NCT ID: NCT06357650 Not yet recruiting - COVID-19 Clinical Trials

Collaborative Open Research Initiative Study (CORIS-1)

CORIS-1
Start date: June 1, 2024
Phase:
Study type: Observational

The Collaborative Open Research Initiative Study (CORIS) is a groundbreaking international research endeavor aimed at exploring vital topics within the field of health professions education. At its core, CORIS embodies the spirit of inclusivity by opening its doors to contributors from all corners of the globe, putting the power of research into the hands of the global community and fostering an environment of open collaboration and meaningful contribution. We invite anyone and everyone to join as collaborators and suggest questions for inclusion in the survey, ensuring that the research process is enriched by diverse perspectives. As a collaborator, you will not only have the opportunity to actively engage in survey design, question formulation, and the entire research process from start to finish, but also gain the prospect of achieving valuable publications, which may boost your professional career.